Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment
NEW BRUNSWICK, N.J. and DUBLIN, July 2 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) and Elan
Corporation plc (NYSE: ELN ) today announced a definitive agreement whereby Johnson & Johnson will acquire substantially all of the assets and rights of Elan
related to its Alzheime...
Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
CORONA, Calif., March 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty pharmaceutical company, announced today that it has reached a settlement with Elan
Corporation, Plc on outstanding patent litigation related to Watson's generic version of Naprelan(R)...
Berger & Montague Announces Class Action Lawsuit Against Elan Corporation
PHILADELPHIA, Oct. 29 /PRNewswire-USNewswire/ -- Berger & Montague
("Berger") announced today that a class action lawsuit was filed in the
United States District Court of New York on behalf of all purchasers of
American Depository Shares (evidenced by American Depository Receipts) of
Transition Therapeutics Receives Remaining Upfront Payment from Elan Corporation, plc
TORONTO, Oct. 26 /PRNewswire-FirstCall/ - Transition Therapeutics Inc.
("Transition") (NASDAQ: TTHI , TSX: TTH) announced the receipt of US$7.5
million representing the second half of the US$15 million upfront payment
under the Company's global collaboration agreement with a subsidiary of
Transition Therapeutics Announces Milestone Payment from Elan
TORONTO, Dec. 24 /PRNewswire-FirstCall/ - Transition Therapeutics Inc.
("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), announced today
that the Company will receive a US$5million milestone payment under its
global collaboration agreement with a subsidiary of Elan
Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results
... served as Senior Vice President of Global Safety, Regulatory Affairs and Quality for Chiron Biopharma, and in similar roles with Nektar Therapeutics, elan
Pharmaceuticals and Novartis Biopharma.
Jay Hagan as Senior Vice President of Corporate Development and Strategy. Jay has spent the bulk of h...
FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
INVEGA SUSTENNA was developed utilizing elan
Drug Technologies' proprietary NanoCrystal(R) Tech...m/ .
About NanoCrystal(R) Technology and elan
INVEGA SUSTENNA utilizes the...gy, which is a proprietary technology developed by elan
Drug Technologies through...
PDL BioPharma Announces Second Quarter 2009 Financial Results
...tin(R), and Lucentis(R), which are marketed by Genentech, Inc., a subsidiary of F. Hoffman-LaRoche Ltd., and sales of Tysabri(R), which is marketed by elan
Corporation Plc. and Biogen Idec Inc. Royalty revenues are based on first quarter 2009 product sales by PDL's licensees and include $18.9 million for...
Victory Pharma, Inc. Announces FDA Accepts MGX006 NDA for Review
...side effects Further information regarding Victory Pharma is available at www.victorypha r ma.com .
NAPRELAN (R) is a trademark of elan
Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015, According to a New Report by Global Industry Analysts
...ts such as Abbott Laboratories, Amgen Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., elan
Corporation, plc, Eli Lilly And Company, F. Hoffmann-La Roche AG, Genentech, Inc., GlaxoSmithKline plc, Johnson & Johnson, Inc., Merck Serono SA, ...
Elan in Medical Technology
Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
.... INVEGA(R) SUSTENNA(TM) was developed utilizing elan
Drug Technologies' proprietary NanoCrystal((R)) Te...
About NanoCrystal ((R)) Technology and elan
INVEGA(R) SUSTENNA(TM) util...gy, which is a proprietary technology developed by elan
Drug Technologies through...
Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
...NILIN(R) monoclonal antibody platform to Wyeth and elan
Pharma International Ltd. The license grants rights to Wyeth and elan
under Intellect's patents with respect to the deve...onoclonal antibody intended to treat AD. Wyeth and elan
are currently testing Bapineuzumab in several thou...
Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research
... to Drug Discovery for PD, a collaboration made
possible by co-funding from elan
(NYSE: ELN ); and the industry-exclusive
Therapeutics Development Initiati...tiative.
Novel Approaches to Drug Discovery for PD
A collaboration with elan
Total available funding: $1.5 million
Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day
...y SODAS(R) (Spheroidal Oral Drug
Absorption System) technology developed by elan
Corporation, where 50% of
the dose is released immediately and the remainin...usive worldwide (except Canada) royalty and manufacturing
agreement between elan
Corporation, plc, and Novartis Pharma AG.
1. Concerta(R) is ...
Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimer's Therapeutic Antibody
...euzumab being developed
independently by Wyeth and elan
Pharma International Ltd. (Elan) in that it
binds ...nical trials. The
recent announcement by Wyeth and elan
of positive Top Line Phase 2 data in
a subset of p...has granted a royalty-bearing
license to Wyeth and elan
Pharma International Ltd. (Elan) regarding
September is National Pain Awareness Month
...ists for those who are suffering in the form of a sea
snail. Researchers at elan
Pharmaceuticals, Inc., a wholly-owned subsidiary
Corporation, plc, have harnessed the venom of the Conus magus sea
Data Presented at the American Academy of Neurology's Annual
Meeting Provide Update on Utilization and Safety of Tysabri in
Patients with Multiple Sclerosis
...IRE)--May 3, 2007 - Biogen Idec (NASDAQ: BIIB)
Corporation, plc (NYSE: ELN) announced today that ... company, please visit
Corporation, plc is a neuroscience-based biotechno...
Archemix Announces Completion of Phase 1 Trial of ARC1779
...g to aptamers has enabled it to form numerous
collaborations with biotechnology and pharmaceutical collaborators,
including Merck Serono, Pfizer Inc., elan
Pharma, Nuvelo, Inc.,
Antisoma plc., and Regado Biosciences. For more information, please
Yates and Asso...
Elan in Biological Technology
Circ Pharma Limited Enters Into Development Agreement for Chrono Tramadol With Elan Corporation Plc
DUBLIN, May 4 /PRNewswire/ -- Circ Pharma Limited ("Circ Pharma") and
Elan Corporation plc ("Elan") today announced that they have entered into a
Development Agreement to develop a chronotherapeutic formulation of Tramadol
for the treatment of moderate to moderately severe pain.
Shareholder Class Action Filed Against Elan Corporation, plc by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
RADNOR, Pa., Dec. 11 /PRNewswire/ -- The following statement was issued today by the law firm of Barroway Topaz Kessler Meltzer & Check, LLP:
Notice is hereby given that a class action lawsuit was filed in the United States District Court for the Southern District of New York on beha...
Azur Pharma and Elan Corporation (NYSE: ELN) Sign Agreement to Develop a Once-Daily Clozapine
DUBLIN, November 10 /PRNewswire/ -- Azur Pharma Limited ("Azur") today
announced that it has entered into an agreement to develop and
commercialise once-daily formulations of clozapine using Elan
plc's ("Elan")(NYSE: ELN ) proprietary drug delivery technologies, including
Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
NEW YORK, May 19 /PRNewswire-FirstCall/ -- Intellect Neurosciences,
Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company focused on
development of disease-modifying therapeutic agents for the treatment and
prevention of Alzheimer's disease (AD), announced today that it has entered
PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan
Promise of revolutionary orally-administered drugs to combat Alzheimer's began journey 8 years ago
"Finding a needle in a haystack - 4 molecules out of a million"
NEW YORK, Aug. 6 /PRNewswire-USNewswire/ -- New therapeutics funded by the Alzheimer's Dr...
Studies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease
...VIENNA, Austria, July 14 /PRNewswire-FirstCall/ -- elan
Corporation, plc (NYSE: ELN ) and Wyeth (NYSE: ...ternational.
Editors Note: The following elan
and Wyeth abstracts were also presented at ICAD: ...usions or hallucinations.
About the elan
and Wyeth Collaboration
The Alzheimer's Immu...
World Nanomedicine Market to Cross $160 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
...nanomedicine market include Abraxis BioScience Inc., AMAG Pharmaceuticals Inc, Arrowhead Research Corporation, Crucell N.V., Flamel Technologies S.A., elan
Corporation Plc, Enzon Pharmaceuticals Inc., Life Technologies Corporation, Nanosphere Inc., Nektar Therapeutics, Novavax Inc., Oxonica Plc, Par Pharm...
PDL BioPharma Announces First Quarter 2009 Financial Results
...tin(R) and Lucentis(R), which are marketed by Genentech, Inc., a subsidiary of F. Hoffman-La Roche Ltd., and sales of Tysabri(R), which is marketed by elan
Corporation, Plc. Royalty revenues are based on fourth quarter product sales by PDL's licensees and include those for Synagis(R), which is marketed by...
Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
... Scaife held the position of Vice President of Quality and Regulatory Affairs for Nektar Therapeutics, Vice President of Global Regulatory Affairs for elan
Pharmaceuticals, and various regulatory and clinical development positions for Novartis Pharma. Dr. Scaife began his career as the Regulatory and Med...
Alkemists Labs Wins Nutrition Business Journal's 2008 Industry Growth Award
...ete. "We've been planning our strategic growth for some time now and are implementing an aggressive approach to meet customer demand," says elan
Sudberg, COO of Alkemists Labs.
The expansion will enable the lab to approximately double the weekly sample load, with a primary emphasis on fast...